Axel Le Cesne
#163,104
Most Influential Person Now
Axel Le Cesne's AcademicInfluence.com Rankings
Axel Le Cesnemedical Degrees
Medical
#3312
World Rank
#3779
Historical Rank
Oncology
#233
World Rank
#241
Historical Rank
Axel Le Cesnebiology Degrees
Biology
#13038
World Rank
#16561
Historical Rank
Immunology
#885
World Rank
#908
Historical Rank
Download Badge
Medical Biology
Axel Le Cesne's Degrees
- PhD Immunology Université Paris Cité
- Masters Biology Université Paris Cité
- Bachelors Biotechnology Université Paris Cité
Similar Degrees You Can Earn
Why Is Axel Le Cesne Influential?
(Suggest an Edit or Addition)Axel Le Cesne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007) (1181)
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. (2006) (836)
- Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) (773)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (624)
- NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) (623)
- Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). (2009) (611)
- Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. (2009) (591)
- Cutaneous side-effects of kinase inhibitors and blocking antibodies. (2005) (537)
- Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. (2009) (494)
- Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. (2009) (482)
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. (2012) (480)
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. (2007) (420)
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. (2012) (414)
- Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. (2005) (413)
- Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. (2007) (376)
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. (2005) (375)
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. (2009) (345)
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. (2001) (324)
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. (2004) (309)
- Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. (2007) (306)
- Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. (2011) (299)
- Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. (2005) (285)
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. (2010) (271)
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial (2018) (264)
- Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. (2013) (263)
- Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. (2008) (258)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (244)
- Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (2007) (240)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (230)
- Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
- Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (216)
- High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. (1995) (207)
- Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (206)
- Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. (2013) (199)
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. (2011) (199)
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. (2011) (199)
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
- Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. (2009) (185)
- Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. (2003) (180)
- Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. (2006) (177)
- Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. (2003) (173)
- Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. (2004) (171)
- Advanced chondrosarcomas: role of chemotherapy and survival. (2012) (171)
- NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. (2019) (170)
- Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). (2012) (168)
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis (2006) (163)
- Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. (1996) (160)
- Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma (2001) (154)
- First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. (2011) (153)
- Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. (1998) (153)
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. (2020) (152)
- The treatment of desmoid tumors: a stepwise clinical approach. (2012) (148)
- Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2000) (147)
- Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (147)
- Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. (2009) (147)
- Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors (2006) (138)
- Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. (2014) (134)
- Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. (1997) (132)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (131)
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. (2012) (131)
- Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. (2015) (130)
- Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study (2017) (127)
- High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management (2010) (126)
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. (2012) (122)
- Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. (2015) (121)
- Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure (2012) (120)
- Improved survival using specialized multidisciplinary board in sarcoma patients (2017) (119)
- Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST (2014) (118)
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). (2010) (116)
- Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. (2014) (116)
- Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (115)
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). (2012) (115)
- Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. (2014) (114)
- Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. (2012) (113)
- Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. (2013) (113)
- Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy (2003) (111)
- Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr (2017) (110)
- Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial (2011) (110)
- Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. (2017) (109)
- Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. (2016) (107)
- Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. (2019) (107)
- Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases (2012) (106)
- Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. (1998) (105)
- Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach? (2009) (103)
- Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. (2016) (100)
- Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). (2016) (100)
- Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. (2014) (100)
- Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). (2006) (99)
- Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. (2009) (99)
- Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. (2007) (98)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study (2019) (96)
- Improved survival using specialized multidisciplinary board in sarcoma patients. (2017) (95)
- Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. (2019) (93)
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. (2015) (92)
- Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† (2015) (90)
- Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk (2014) (89)
- Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. (2015) (88)
- Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. (2011) (86)
- Corrections to "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (86)
- Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (2011) (85)
- Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. (2015) (85)
- Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (85)
- Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database (2017) (84)
- Sorafenib in patients with progressive epithelioid hemangioendothelioma (2013) (84)
- Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. (2019) (84)
- Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. (2021) (83)
- Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. (2004) (83)
- Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. (2005) (82)
- Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. (2015) (82)
- A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. (2017) (81)
- Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. (2013) (80)
- Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma (2008) (79)
- Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. (1999) (77)
- Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. (2018) (77)
- Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? (2003) (76)
- Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network (2020) (76)
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (2013) (73)
- Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. (2011) (73)
- Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. (2010) (73)
- Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? (2005) (72)
- Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. (2005) (71)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (71)
- Adjuvant therapy in primary GIST: state-of-the-art. (2012) (69)
- Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? (2013) (69)
- Docetaxel and interstitial pulmonary injury. (1997) (69)
- Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2020) (67)
- Spermatic cord sarcoma in adults. (1999) (66)
- Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. (2016) (64)
- Can the MRI signal of aggressive fibromatosis be used to predict its behavior? (2009) (64)
- Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) (2019) (64)
- GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. (2013) (64)
- Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database (2019) (64)
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. (2012) (64)
- TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma (2016) (63)
- Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. (2014) (62)
- ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma (2011) (61)
- RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. (2005) (61)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study. (2019) (58)
- PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas (2017) (58)
- Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials (2019) (57)
- Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. (2019) (57)
- Primary Extremity Soft Tissue Sarcomas: Does Local Control Impact Survival? (2016) (57)
- Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. (2009) (56)
- A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. (2004) (56)
- Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. (2016) (56)
- Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. (2018) (55)
- A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. (1998) (55)
- Basic Knowledge in Soft Tissue Sarcoma (2019) (55)
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities (2021) (53)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial (2014) (53)
- Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. (2009) (53)
- A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. (2008) (52)
- Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib (2005) (52)
- Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester. (1999) (51)
- Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics (2013) (48)
- Corrections to "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (47)
- Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (2007) (47)
- Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2019) (45)
- Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. (2016) (45)
- Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. (2012) (44)
- Prognosis and predictive value of KIT exon 11 deletion in GISTs (2009) (44)
- Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis (2010) (43)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (43)
- Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. (2013) (43)
- Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (2012) (42)
- Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). (2017) (42)
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients (2017) (42)
- Imatinib in the treatment of solid tumours (2009) (42)
- Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group (2015) (42)
- Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. (2005) (40)
- Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. (2009) (40)
- Epithelioid Sarcoma: Need for a Multimodal Approach to Maximize the Chances of Curative Conservative Treatment (2013) (39)
- REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis (2017) (39)
- Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. (2014) (39)
- Improving treatment results with reference centres for rare cancers: where do we stand? (2017) (38)
- Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network (2015) (38)
- PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (37)
- Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. (2015) (37)
- Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. (2004) (37)
- Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. (2020) (36)
- Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study (2018) (36)
- Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. (1999) (35)
- Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). (2009) (35)
- Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib (2017) (34)
- Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). (2015) (34)
- Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival (2015) (34)
- Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs (2008) (34)
- Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts (2021) (34)
- Postoperative radiotherapy in the management of adult soft tissue sarcoma of the extremities: results with two different total dose, fractionation, and overall treatment time schedules. (1999) (33)
- High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. (2004) (32)
- [Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]. (2006) (32)
- Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07) (2018) (31)
- Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (2012) (31)
- Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). (2014) (30)
- Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) (2018) (30)
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). (2012) (30)
- Cisplatin‐based chemotherapy regimen (DECAV) for uterine sarcomas (2002) (29)
- Perioperative Management of Extremity Soft Tissue Sarcomas. (2018) (29)
- Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. (2019) (28)
- Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. (2020) (27)
- Should the number of pulmonary metastases influence the surgical decision? (1997) (27)
- Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial (2015) (27)
- The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group (2018) (26)
- A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. (2019) (26)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
- [Metastases from cancers of unknown primary site. Data from 302 autopsies]. (1991) (26)
- Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. (2020) (26)
- Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours. (1997) (25)
- Unusual problems in breast cancer and a rare lung cancer case. Case 2. Aggressive fibromatosis of the chest wall arising near a breast prosthesis. (2003) (25)
- Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-&agr; for Locally Advanced Cancers: Encouraging Results of a Phase II Study (2012) (24)
- Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. (2006) (24)
- Targeted cancer therapies. (2005) (24)
- Red marrow recolonization induced by growth factors mimicking an increase in tumor volume during preoperative chemotherapy: MR study. (1997) (24)
- Soft tissue and bone sarcomas in association with pregnancy. (1998) (23)
- Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. (2018) (22)
- Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network (2019) (22)
- Phase I clinical trial combining imatinib mesylate and IL-2 (2013) (22)
- Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma (2020) (22)
- [Recommendations for the management of GIST patients]. (2005) (22)
- The off-label use of targeted therapies in sarcomas: the OUTC’S program (2014) (22)
- Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. (2014) (22)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study (2019) (22)
- A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. (2009) (22)
- Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. (2018) (21)
- Toward a new strategy in desmoid of the breast? (2015) (21)
- The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma (2018) (21)
- The open reading frame I (ORF I)/ORF II part of the human T-cell leukemia virus type I X region is dispensable for p40tax, p27rex, or envelope expression (1994) (20)
- Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. (2004) (20)
- Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. (2012) (20)
- Is preoperative radiotherapy suitable for all patients with primary soft tissue sarcoma of the limbs? (2014) (20)
- Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas (2019) (20)
- Adjuvant therapy in primary GIST: state-of-the-art. (2012) (20)
- Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (2011) (19)
- Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? (1999) (19)
- Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression. (2013) (19)
- Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. (2011) (19)
- Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future (2015) (19)
- A role for maintenance therapy in managing sarcoma. (2012) (19)
- Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. (2009) (18)
- Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study. (2018) (18)
- Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma. (2018) (17)
- The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. (2020) (17)
- French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak (2020) (17)
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. (2012) (17)
- A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas (2019) (17)
- Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. (2006) (16)
- A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. (2020) (16)
- p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. (2008) (16)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. (2014) (15)
- Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (2011) (15)
- PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target (2019) (15)
- Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. (2018) (15)
- Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. (2015) (15)
- A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery (2021) (15)
- [French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak]. (2020) (14)
- Soft tissue sarcomas in HIV-infected adult patients. (1996) (14)
- Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study (2020) (14)
- Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. (2011) (14)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
- Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s) (2017) (14)
- Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? (2006) (14)
- Targeting the VEGF Pathway in Osteosarcoma (2021) (13)
- Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. (2018) (13)
- First-Line Vinorelbine-Mitoxantrone Combination in Metastatic Breast Cancer Patients Relapsing after an Adjuvant Anthracycline Regimen: Results of a Phase II Study (1998) (13)
- Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. (2006) (13)
- Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. (2011) (12)
- Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). (2006) (12)
- Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/ French Sarcoma Group phase II trial. (2016) (12)
- A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. (2021) (12)
- Management of locoregional recurrence after radical resection of a primary nonmetastatic retroperitoneal soft tissue sarcoma: The Gustave Roussy experience (2018) (12)
- A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT. (2006) (12)
- Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions (2020) (12)
- The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments (2020) (12)
- Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series (2017) (12)
- The importance of treating by histological subtype in advanced soft tissue sarcoma. (2017) (12)
- Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial (2022) (12)
- Making the Best of Available Options for Optimal Sarcoma Treatment (2018) (12)
- A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). (2009) (11)
- Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour? (2009) (11)
- Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST) (2016) (11)
- Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial (2018) (11)
- Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. (2011) (11)
- Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial. (2006) (11)
- Primary pleuropulmonary sarcoma: a rare disease entity. (2012) (10)
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients (2013) (10)
- Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years (2019) (9)
- Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. (2006) (9)
- Determinants of the access to remote specialised services provided by national sarcoma reference centres (2021) (9)
- Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study (2021) (9)
- Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status (2020) (9)
- Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. (2004) (9)
- Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. (2019) (9)
- Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial (2018) (8)
- The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value (2015) (8)
- Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. (2011) (8)
- Postoperative Outcome of Surgery with Pancreatic Resection for Retroperitoneal Soft Tissue Sarcoma: Results of a Retrospective Bicentric Analysis on 50 Consecutive Patients (2020) (8)
- INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib (2022) (8)
- Liver metastases from extremity soft tissue sarcoma. (1999) (8)
- Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma (2020) (8)
- Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. (2016) (8)
- Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): Results of the French Sarcoma Group phase II trial. (2009) (7)
- Surrogate endpoints in advanced sarcoma trials: a meta-analysis (2018) (7)
- Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial (2022) (7)
- Recent advances in managing gastrointestinal stromal tumor (2017) (7)
- [Soft tissue sarcomas: general review]. (1994) (7)
- Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial. (1994) (7)
- Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. (2018) (7)
- Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours. (1996) (7)
- Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience (2019) (7)
- Key messages from the BFR14 trial of the French Sarcoma Group. (2017) (7)
- A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. (2020) (7)
- 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? (2013) (7)
- Algorithm for the Surgical Management of Mesenchymal Tumors of the Perineum in Adults (2015) (7)
- Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma (2020) (6)
- Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians. (2011) (6)
- Criteria for reference centers for sarcomas: volume but also long term multidisciplinary organisation. (2019) (6)
- Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. (2018) (6)
- Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. (2015) (6)
- [Standards, options, and recommendations for the use of hematopoietic growth factors in oncology]. (2000) (6)
- Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA) (2020) (6)
- Individualized Pazopanib Dosing—Letter (2016) (6)
- Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. (2019) (6)
- Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts). (2011) (6)
- Pressure-suit combined with pelvic stop-flow: a feasibility study in a bovine model. (2007) (6)
- [Management of recurrent soft tissue sarcoma of the retroperitoneum]. (2004) (5)
- Is dose de-escalation possible in sarcoma patients treated with enlarged limb sparing resection? (2017) (5)
- Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer. (1995) (5)
- Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. (2019) (5)
- Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors. (2014) (5)
- Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature (2022) (5)
- [Medical therapy of GIST; from palliative to curative treatment]. (2012) (5)
- ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol (2019) (5)
- Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors (2017) (5)
- Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature (2022) (4)
- Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study (2020) (4)
- [Recommendations for diagnostic and therapeutic management of soft tissue sarcoma]. (2009) (4)
- 1418PDLONG-TERM OUTCOME OF DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER TWO STAGE PHASE II TRIAL SAKK 56/07. (2014) (4)
- Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas (2021) (4)
- [Recommendations for the management of gastro-intestinal stromal tumors]. (2006) (4)
- An unusual variant of diffuse retinoblastoma in an adult (2008) (4)
- Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses (2021) (4)
- [Gastro-intestinal stromal tumors: news and comments]. (2003) (4)
- Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments. (2018) (4)
- [Neoadjuvant chemotherapy in sarcoma]. (2006) (4)
- Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. (2022) (4)
- 1415OOUTCOME OF FIRST-LINE TREATMENT OF ELDERLY ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS: A POOLED ANALYSIS OF ELEVEN EORTC SOFT TISSUE AND BONE SARCOMA GROUP TRIALS. (2014) (4)
- Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST). (2011) (4)
- Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas (2018) (3)
- Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group. (2018) (3)
- Surgical management of soft tissue tumors of the abdominal wall: A retrospective study in a high‐volume sarcoma center (2021) (3)
- Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group (2021) (3)
- [Free-flap reconstruction of locally advanced soft tissue sarcomas]. (2001) (3)
- TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials (2021) (3)
- Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis. (2019) (3)
- Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpression. (2022) (3)
- Improving at a nationwide level the management of patients with sarcomas with an expert network. (2022) (3)
- Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT. (2022) (3)
- Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting (2019) (3)
- [Chondrosarcoma in Ollier's disease. Apropos of 2 cases and review of the literature]. (1998) (3)
- Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial. (2019) (3)
- Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study (2021) (3)
- [New therapeutic strategies and current research in inoperable locally advanced non small-cell lung cancers (stage IIIB)]. (1997) (3)
- Chemotherapy in the management of periosteal osteosarcoma: A narrative review (2021) (3)
- ELYPSE 2: A prospective randomized trial comparing filgrastim (G-CSF) in primary and secondary prophylaxis in patients (pts) at high risk for febrile neutropenia (FN). (2006) (3)
- Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group. (2011) (3)
- Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) (2022) (3)
- KIT expression in postradiation sarcoma (2009) (2)
- Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. (2022) (2)
- Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. (2022) (2)
- [Intensity modulated radiotherapy as adjuvant post-operative treatment for retroperitoneal sarcoma: acute toxicity]. (2011) (2)
- Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE. (2023) (2)
- Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials (2022) (2)
- Pazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience. (2018) (2)
- [Diagnosis and treatment of gastrointestinal stromal tumours]. (2006) (2)
- Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. (1995) (2)
- [Function preserving surgery of limb sarcomas: history and improvements]. (2006) (2)
- No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome? (2022) (2)
- Outcome of patients with advanced GIST achieving a complete remission (CR) with imatinib (IM) before interruption: Pooled analysis of two consecutive prospective randomizations of the French Sarcoma Group BFR14 phase III trial. (2009) (2)
- Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG). (2011) (2)
- Indeterminate bone lesion: the diagnosis (2002) (2)
- Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma (2020) (2)
- Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients (2012) (2)
- 1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network (2022) (2)
- Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. (2011) (2)
- Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts. (2022) (2)
- 1414OBENEFIT OF MAINTENANCE THERAPY WITH TRABECTEDIN (T) BEYOND THE 6 FIRST CYCLES: RESULTS OF A PROSPECTIVE RANDOMIZED PHASE II TRIAL COMPARING INTERRUPTION VS. CONTINUATION OF T IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (ASTS): AN UPDATE. (2014) (2)
- 1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion (2022) (2)
- Prognostic factors of the synovial sarcoma of the extremities: imaging does matter (2022) (2)
- [Surgery of retroperitoneal sarcomas]. (2006) (2)
- When Imaging Becomes Clinically Relevant: Multikinase Inhibitor-related Pancreatic Insufficiency and Pancreatic Atrophy. (2017) (2)
- Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators (2022) (1)
- Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
- Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (2013) (1)
- [Preoperative versus postoperative radiotherapy in soft tissue sarcomas: State of the art and perspectives]. (2021) (1)
- [Focus on GIST management]. (2010) (1)
- Frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis as a surrogate marker for disease management. (2009) (1)
- Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. (1995) (1)
- [Chemotherapy of metastatic soft tissue sarcoma]. (1995) (1)
- A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma. (2022) (1)
- Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients. (2018) (1)
- Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy – brachytherapy association (2022) (1)
- [Dose-effect of chemotherapy in bronchial small-cell cancer]. (1997) (1)
- Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume? (2021) (1)
- Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study (2020) (1)
- Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis (2022) (1)
- Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft-tissue sarcoma patients. (2020) (1)
- [Place and technical aspects of external beam radiation therapy in the treatment of adult soft tissue sarcomas]. (2006) (1)
- [Docetaxel and non-small cell lung cancer]. (2004) (1)
- Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor (GIST): A study based on the EORTC-ISG-AGITG trial 62005. (2016) (1)
- The off-label use of targeted therapies in sarcomas: the OUTC’S program (2014) (1)
- Intensive induction chemotherapy (API-AI regimen) followed by conservative surgery in adult patients with locally advanced soft tissue sarcoma (STS): Survival is predicted by the histological response. (2004) (1)
- 1523MO Initial active surveillance strategy for patients with peripheral sporadic desmoids: A multicentre phase II observational trial (2021) (1)
- 48MO Characteristics and outcomes of 76 patients with pleomorphic liposarcoma: The Gustave Roussy experience (2023) (0)
- Experience with second-line trabectedin in daily clinical practice: case studies. (2022) (0)
- Pain in desmoid-type fibromatosis: prevalence, determinants, and prognosis value. (2023) (0)
- Corrigendum to 'Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study' [Eur J Cancer 171 (2022) 183-192]. (2023) (0)
- Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST. (2018) (0)
- Reflexions from the experience of the French CLEOPATRE program and concerns about the status of clinical research on small cell lung cancer. (2001) (0)
- [Metastatic extraskeletal osteosarcoma revealed by an occipital mass]. (2008) (0)
- Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age (2023) (0)
- Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas (2002) (0)
- Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial (2015) (0)
- Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group (2015) (0)
- Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. (2023) (0)
- Neoadjuvant chemotherapy associated with enhanced local control in radiation-induced angiosarcoma of breast and chest (2023) (0)
- Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes. (2022) (0)
- [Breast cancer: chemotherapy as salvage after failure of locoregional treatment by exclusive radiotherapy]. (1989) (0)
- A case of intracardiac RREB1::MKL2 spindle cell mesenchymal tumor. (2023) (0)
- 1512P Pain in patients with desmoid fibromatosis (DF) (2022) (0)
- Determinants of the access to remote specialised services provided by national sarcoma reference centres (2021) (0)
- Cutaneous genital complications of antiangiogenic agents. (2009) (0)
- Use of extent surgery via intraperitoneal route to improve iliopsoas sarcoma local control. (2011) (0)
- Distribution and Outcome of NTRK-Rearranged Mesenchymal Tumors (NMT): An Ambispective Cases Series (2022) (0)
- Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) (2022) (0)
- Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response (2021) (0)
- PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (0)
- Study of dynamic contrast-enhanced ultrasound (DCE-US) for the early evaluation of imatinib. (2011) (0)
- No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: Results from a single center propensity-matched analysis. (2018) (0)
- Metastatic risk stratification of leiomyosarcoma patients using transcription- and replication-associated chromosomal instability mechanisms (2021) (0)
- 83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials (2021) (0)
- 1430PIDENTIFYING BIOLOGICAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) RESPONDING TO IMATINIB THERAPY FOR MORE THAN 5 AND 10 YEARS. (2014) (0)
- CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response (2022) (0)
- The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data. (2022) (0)
- Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial (2018) (0)
- 1551P Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léon Bérard and Gustave Roussy experience (2021) (0)
- [Importance of the initial chemotherapy dose in the treatment of small cell lung carcinoma: therapeutic perspectives]. (1995) (0)
- Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (0)
- Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome (2021) (0)
- Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib (2022) (0)
- Handling missing covariates in observational studies: An illustration with the assessment of prognostic factors of survival outcomes in sarcoma in irradiated fields (SIF). (2022) (0)
- 1515P Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020) (2022) (0)
- Intensive induction chemotherapy (CT) without methotrexate (MTX) in adult patients with localized osteosarcoma (LO): Updated results of the Institut Gustave Roussy phase II trial. (2004) (0)
- P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study (2022) (0)
- Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA) (2020) (0)
- Malignant gastrointestinal stromal tumors treated with imatinib in France: Results in unselected patients. (2009) (0)
- Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: Results of a retrospective series in a tertiary care center. (2018) (0)
- Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment (2020) (0)
- 91P Liquid biopsy, a tool to detect genetic alterations with therapeutic impact in international patients: Prospective data on 47 patients from Gustave Roussy (2022) (0)
- [Urothelial carcinoma on vesico-renal bilharziosis with multiple bone metastases]. (1990) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Axel Le Cesne?
Axel Le Cesne is affiliated with the following schools:
